{
    "title": "114_hr2335",
    "content": "The Act titled \"Stop Tampering of Prescription Pills Act of 2015\" aims to implement abuse-deterrent technology. The \"Stop Tampering of Prescription Pills Act of 2015\" introduces the definition of an abuse-deterrent drug as a controlled substance formulated for oral administration with properties that make manipulation difficult for misuse or abuse. The \"Stop Tampering of Prescription Pills Act of 2015\" defines abuse-deterrent drugs as controlled substances formulated to deter misuse or abuse, containing additional ingredients to prevent abuse through pharmacological effects. Application for approval of brand name drugs must include necessary information to demonstrate compliance with abuse-deterrent requirements. The \"Stop Tampering of Prescription Pills Act of 2015\" requires that brand name drugs formulated for oral administration containing controlled substances classified as opium or derivatives must not be abuse-deterrent drugs to be approved. The \"Stop Tampering of Prescription Pills Act of 2015\" mandates that brand name drugs with controlled substances must not be abuse-deterrent to be approved. Section 505(j) of the Federal Food, Drug, and Cosmetic Act is amended to address drug shortages and public health needs. The \"Stop Tampering of Prescription Pills Act of 2015\" requires that brand name drugs with controlled substances must not be abuse-deterrent to be approved. Section 505(j) of the Federal Food, Drug, and Cosmetic Act is amended to address drug shortages and public health needs. Amendment to the Cosmetic Act (21 U.S.C. 355(j)) includes criteria for abuse-deterrent drugs based on physicochemical properties and testing to demonstrate resistance to manipulation. The \"Stop Tampering of Prescription Pills Act of 2015\" amends Section 505(j) of the Federal Food, Drug, and Cosmetic Act to address drug shortages and public health needs. The amendment includes criteria for abuse-deterrent drugs based on physicochemical properties and testing to demonstrate resistance to manipulation. The amendment also specifies that the listed drug must not be abuse-deterrent to be approved. The amendment to Section 505(j) of the Federal Food, Drug, and Cosmetic Act sets criteria for abuse-deterrent drugs and states that a drug approved under this section must meet specific requirements if the listed drug becomes abuse-deterrent. The amendment to Section 505(j) of the Federal Food, Drug, and Cosmetic Act outlines criteria for abuse-deterrent drugs. It specifies that a drug formulated for oral administration will be considered withdrawn or suspended for safety or effectiveness reasons if a listed drug, not an abuse-deterrent, is withdrawn or suspended, and if a drug in the same dosage form with the same controlled substances has been previously approved by the Secretary. The amendment to Section 505(e) of the Federal Food, Drug, and Cosmetic Act specifies criteria for withdrawing previously approved brand name and generic drugs. It includes conditions such as containing a controlled substance classified as opium, being formulated for oral administration, not being an abuse-deterrent drug, and having not been discontinued from marketing. The amendment to Section 505(e) of the Federal Food, Drug, and Cosmetic Act outlines criteria for withdrawing approved drugs, including those with controlled substances, formulated for oral use, not abuse-deterrent, and not discontinued from marketing. The Secretary may waive certain requirements for drugs intended for special needs populations. The Stop Tampering of Prescription Pills Act of 2015 requires the Secretary to list abuse-deterrent drugs and update the list accordingly. The Stop Tampering of Prescription Pills Act of 2015 mandates the Secretary to update the list of abuse-deterrent drugs."
}